Dr. Jean-Yves Blay

• 
  production.biovalley.com/dn_biovalley_news/TransgeneAdv - [Cached Version]
  Published on: 12/18/2006    Last Visited: 4/22/2007  

  Jean-Yves Blay, M.D., Ph.D.Jean-Yves Blay is Professor of Medical Oncology at the University Lyon 1, Scientific Director of Cancéropôle Lyon Rhône-Alpes, France.

• 
  AMN-107 Talk - [Cached Version]
  Published on: 7/26/2004    Last Visited: 12/19/2006  

  Investigator: Jean-Yves Blay, M.D.

• 
  ARIAD - News Release - [Cached Version]
  Published on: 10/6/2008    Last Visited: 5/29/2008  

  Expanded data, originally disclosed at the 17th AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" in Philadelphia, were presented by Professor Jean-Yves Blay, one of the lead European clinical investigators in the AP23573 clinical trials and chairman of the EORTC-STBSG.
  
  Presented data from several preclinical studies on ARIAD's pipeline product candidates at the American Association for Cancer Research (AACR) annual meeting.

• 
  ARIAD Reports First Quarter 2006 Results: Financial... - [Cached Version]
  Published on: 5/9/2006    Last Visited: 5/9/2006  

  Expanded data, originally disclosed at the 17th AACR-NCI-EORTC International Conference on "Molecular Targets and Cancer Therapeutics" in Philadelphia, were presented by Professor Jean-Yves Blay, one of the lead European clinical investigators in the AP23573 clinical trials and chairman of the EORTC-STBSG.Presented data from several preclinical studies on ARIAD's pipeline product candidates at the American Association for Cancer Research (AACR) annual meeting.

• 
  CNW Group - [Cached Version]
  Published on: 12/18/2006    Last Visited: 12/18/2006  

  Jean-Yves Blay, M.D., Ph.D.
  
  Jean-Yves Blay is Professor of Medical Oncology at the University Lyon I, Scientific Director of Canceropole Lyon Rhone-Alpes, France.

• 
  Canada NewsWire - [Cached Version]
  Published on: 6/7/2004    Last Visited: 6/7/2004  

  "As we look at the benefits of Glivec(R) over long-term use, the results continue to be very impressive," said Dr. Jean-Yves Blay, lead investigator, Centre Léon Bérard, Hôpital Edouard Herriot, and scientific director of the Cancéropôle Lyon Rhône-Alpes Auvergne, Lyon, France.

• 
  Glivec(R) should not be interrupted in patients with... - [Cached Version]
  Published on: 6/6/2004    Last Visited: 6/8/2004  

  "As we look at the benefits of Glivec® over long-term use, the results continue to be very impressive," said Dr. Jean-Yves Blay, lead investigator, Centre Léon Bérard, Hôpital Edouard Herriot, and scientific director of the Cancéropôle Lyon Rhône-Alpes Auvergne, Lyon, France.

• 
  MEB - [Cached Version]
  Published on: 5/25/2007    Last Visited: 3/8/2008  

  Jean-Yves Blay, M.D., Ph.D. and Denise Reinke, APRN, BC, AOCN Join Medical Editorial Board.
  ...
  Jean-Yves Blay, MD, PhD
  
  Jean-Yves Blay, MD, PhD, is a Professor of Medicine at the Université Claude Bernard in Lyon, France and the Scientific Director of the Cancéropôle Lyon Rhône-Alpes, a network of more than 1500 researchers and physicians in the French Rhône-Alpes region bridging clinical, translational and basic research in oncology.Dr. Blay received a medical degree and a doctorate from the Université Claude Bernard and completed a fellowship in oncology and internal medicine at Université Claude Bernard Lyon 1 and the Institut Gustave-Roussy in Paris.He subsequently joined the staff of the Comprehensive Cancer Center Leon Berard in Lyon, ultimately becoming Head of the Cytokine and Cancer Unit within an Institut National de la Santé et de la Recherche Médicale (INSERM) research unit.He assumed the position as Head of the Medical Oncology Unit in University Hospital in Lyon in 1999, becoming Scientific Director of Cancéropôle Lyon Rhône-Alpes in 2004.Dr. Blay's research interests center on clinical and biological research in the field of soft tissue sarcomas, as well as on the biology of breast carcinoma and the relationship between tumor microenvironment and malignant cells, with the ultimate goal of clinical applications in the fields of diagnosis, prognosis, and treatment.Dr. Blay's professional endeavors mirror his research interests.He is a contributor to the medical literature and has more than 150 peer-reviewed articles and over 200 abstracts and book chapters to his credit.Writing for such journals as Blood, Cancer, Annals of Oncology, Journal of Clinical Oncology, and the European Journal of Cancer, he addresses a range of subjects that includes the role of interleukins, sarcomas of the soft tissues, and the role of dendritic cells in boosting antitumor response.Dr. Blay is active in numerous professional organizations, most prominently the European Organization for Research and Treatment of Cancer (EORTC), of which he is currently Chairman of the Soft Tissue and Bone Sarcoma Group, Vice Chairman of the Translational Research Advisory Committee, and member of the Protocol Review Committee.He is the Chairman of the Strategic Clinical Research Committee of the French Federation of Cancer Centers and Current Chairman of the Connective Tissue Cancers Network (CONTICANET) Network of Excellence supported by the Sixth Framework Program of the European Commission.Dr. Blay is the National Representative for the European Society for Medical Oncology (ESMO) and an active member of the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).Additionally, he has served as a member of scientific committees for ESMO and AACR meetings.

• 
  New Study Finds Interruption of Glivec (imatinib) in... - [Cached Version]
  Published on: 6/7/2004    Last Visited: 6/7/2004  

  "As we look at the benefits of Glivec(R) over long-term use, the results continue to be very impressive," said Dr. Jean-Yves Blay, lead investigator, Centre LC)on BC)rard, HC4pital Edouard Herriot, and scientific director of the CancC)ropC4le Lyon RhC4ne-Alpes Auvergne, Lyon, France.

• 
  Roger - [Cached Version]
  Published on: 1/1/2007    Last Visited: 4/21/2008  

  So when an email arrived from Professor Jean-Yves Blay, one of the leading sarcoma oncologists in France, it was something to be taken seriously.
  
  Like my colleagues in patient groups around Europe (there are not many of us!!) I had heard of Conticanet - an initiative led by Professor Blay to create a network of sarcoma specialist units undertaking clinical research.It is supported by the European Commission.One of the plans for Conticanet is to work with patient groups to see how accrual of patients into clinical trials can be improved.
  
  Given the fragmented nature of patient support and the relative newness of patient groups in Europe the first step was clearly to put these groups into contact with each other and this was the purpose of the email - a meeting in Paris shortly before Christmas 2006.In fact, most of us know one another already through the activities of the European Cancer Patient Coalition (ECPC) and the work of the annual New Horizons conference (supported by Novartis) which brings together CML and GIST patient groups worldwide.But Professor Blay created a new agenda, one which we are investigating more fully.
  
  Photo: Sarcoma patient groups from France, UK and Germany meet with Professor Jean-Yves Blay of Conticanet to discuss European networking.Pictured: Back row: Mariek Podevin (SOS Desmoid - France)), Dr Simon Bacconnier (Conticanet), Kai Pilgermann (Das Lebenshaus - Germany), Roger Wilson (Sarcoma UK), Estelle Le Cointe - (Ensemble contre le GIST - France), Vincent-Olivier Beldon (Grafs - France); Front row: Markus Wartenberg (Das Lebenshaus - Germany), David Robinson (GIST Support UK), Professor Jean-Yves Blay (Conticanet), Judith Robinson (GIST Support UK)

Page:  1 2